Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, multicenter phase III clinical study on the efficacy and safety of tenapanor in the treatment of hyperphosphatemia in patients with end-stage renal disease-hemodialysis (ESRD-HD)

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo-controlled, multicenter phase III clinical study on the efficacy and safety of tenapanor in the treatment of hyperphosphatemia in patients with end-stage renal disease-hemodialysis (ESRD-HD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Hyperphosphataemia
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 26 Feb 2025 According to a Fosun Pharma media release,the company announced that it has received approval from the National Medical Products Administration (NMPA) for the New Drug Application (NDA) for Tenapanor Hydrochloride Tablets.
    • 29 Feb 2024 New trial record
    • 12 Jul 2023 According to a Fosun Pharma USA media release, based on results form this study the company has submitted the New Drug Application (NDA) for Tenapanor Hydrochloride Tablets (the New Drug) for the control of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on hemodialysis which was accepted for review by the National Medical Products Administration (NMPA).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top